|
Vasopressor Agents in Pulmonary Hypertension Crisis
RECRUITINGN/ASponsored by China National Center for Cardiovascular Diseases
Actively Recruiting
PhaseN/A
SponsorChina National Center for Cardiovascular Diseases
Started2026-08-19
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07667829
Summary
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: 1. Age \> 18 years old; 2. Signed informed consent form; 3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH); 4. Presenting with manifestations of pulmonary hypertensive crisis; 5. Receiving both diagnosis and treatment in-hospital; 6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment. Exclusion Criteria: 1. At SCAI stage D or stage E ; 2. Patients who only receive a diagnosis but no treatment in the hospital; 3. Uncontrolled hyperthyroidism; 4. Complicated with angle-closure glaucoma; 5. Hypersensitivity to the study drug; 6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane; 7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide); 8. Pregnancy; 9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.
Conditions4
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Heart DiseaseHypertension, PulmonaryPulmonary Arterial Hypertension (PAH)
Interventions3
Related trials
- Epinephrine Dose: Optimal Versus Standard Evaluation Trial — Unity Health Toronto
- Vasoactive Drugs in Intensive Care Unit — University of Chicago
- R.E.C.K vs Exparel in Robotic Nephrectomy — Wake Forest University Health Sciences
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) — Merck Sharp & Dohme LLC
- Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock — Chonnam National University Hospital
- Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study — Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study — Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery — University of California, San Francisco
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorChina National Center for Cardiovascular Diseases
Started2026-08-19
Est. completion2028-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07667829